Navigation Links
Use of amino acid supplement following a heart attack provides no benefit, may be harmful

Use of the amino acid supplement L-arginine following a heart attack does not improve certain cardiac functions and measurements and may be associated with an increased risk of death, according to a study in the January 4 issue of JAMA.

L-arginine is a widely available dietary supplement and is publicized as having benefits for patients with hypertension, angina, heart failure and sexual dysfunction, according to background information in the article. Prior studies suggest that L-arginine has the potential to reduce vascular (blood vessel) stiffness.

Steven P. Schulman, M.D., of Johns Hopkins Medical Institutions, Baltimore, and colleagues conducted the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) clinical trial to test whether administering L-arginine to patients following a first ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack) over a 6-month period would decrease vascular stiffness and improve ejection fraction (a measure of how much blood the left ventricle of the heart pumps out with each contraction).

The randomized, double-blind, placebo-controlled trial included 153 STEMI patients; 77 were 60 years or older. Participants were enrolled from February 2002 to June 2004. Patients were randomly assigned to receive L-arginine (goal dose of 3 g three times a day) or matching placebo for six months.

The researchers found: "The VINTAGE MI study demonstrated that 6 months of L-arginine added to standard postinfarct medications did not reduce noninvasive measures of vascular stiffness, improve ejection fraction, or improve clinical outcomes. To the contrary, we noted a possible increased risk of death in older patients after infarction while taking L-arginine compared with those taking a placebo, leading to the early termination of the study. These findings have broad public health implications given the increasing availability and use of L-argin ine in patients with and without established cardiovascular diseases."

Death occurred in 6 patients (8.6 percent) in the L-arginine group died during the 6-month study period vs. none in the placebo group.

"In conclusion, L-arginine therapy should not be given to patients following a myocardial infarction. It neither alters noninvasive measures of vascular stiffness nor improves left ventricular function. L-arginine therapy in older patients with diffuse atherosclerosis may worsen clinical outcomes," the authors write.


'"/>

Source:JAMA and Archives Journals


Related biology news :

1. Conserved amino acids play both structural and mechanistic roles in sandwich-like protein
2. New technique helps researchers determine amino-acid charge
3. Changes in amino acids in the 1918 influenza virus cut transmission
4. Women cautioned against using herbal supplements
5. Zinc supplements safe for HIV-infected children
6. Major WHO study concludes calcium supplements can reduce complications during pregnancy
7. Cell death following blood reflow injury tracked to natural toxin
8. High levels of blindness in southern Sudan following years of war
9. PNAS study reveals why organs fail following massive trauma
10. Palaus coral reefs show differential habitat recovery following the 1998 bleaching event
11. UCSD team discovers specialized, rare heart stem cells in newborns
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Maine (PRWEB) , ... January 17, 2017 , ... ... the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification / ... Factor in a human serum base. Each VALIDATE® SP2 kit is prepared using ...
(Date:1/17/2017)... 17, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... 2016 sales and earnings conference call will be broadcast ... at 8 a.m. Eastern Time.  A news release detailing ... at 7:30 a.m. Eastern Time the morning of the ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:1/17/2017)... , Jan. 17, 2017  Northwell Health today ... advance of precision cancer research. ... largest health care provider, Northwell Health diagnoses and ... GmbH is a Germany -based ... therapies. Together they will greatly expand cancer biobanking ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, a ... announced a collaboration with the Heidelberg University Hospital and the German Cancer Research ... following the company’s successful launch of its CATS (Capture and Amplification by ...
Breaking Biology Technology: